Corrigenda: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a Phase III study

Research output: Contribution to journalComment/debate

4 Citations (Scopus)
Original languageEnglish
Article numberPMID 31406976
JournalAnnals of Oncology
DOIs
Publication statusPublished - 2019

Cite this